Prime Medicine Secures Up to $24 Million from CF Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

Reuters

2025/07/16

Prime Medicine Secures Up to $24 Million from CF Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

CAMBRIDGE, Mass., July 16, 2025 - Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company focused on developing innovative genetic therapies, has announced a significant boost in funding with up to $24 million from the Cystic Fibrosis Foundation (CF Foundation). This additional investment aims to accelerate the development of Prime Editors, which are designed to permanently correct cystic fibrosis-related lung disease. The funding will be provided in two tranches, contingent on certain closing conditions and scientific milestones. Prime Medicine plans to initially target the G542X mutation, a prevalent CF-causing nonsense mutation with no current therapies available. The CF Foundation's commitment underscores its confidence in Prime Editing as a transformative approach for cystic fibrosis, with the potential to treat a majority of those affected by the disease. This funding is a continuation of the support established in a January 2024 agreement and highlights the strategic collaboration between Prime Medicine and the CF Foundation to drive innovative solutions for cystic fibrosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9495225-en) on July 16, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2551205147"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551205147\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551205147?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-16 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551205147","market":"nz","top_or_hot":-1,"title":"Prime Medicine Secures Up to $24 Million from CF Foundation to Advance Prime Editing Treatments for Cystic Fibrosis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Prime Medicine Secures Up to $24 Million from CF Foundation to Advance Prime Editing Treatments for Cystic Fibrosis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CAMBRIDGE, Mass., July 16, 2025 - <a href=\"https://laohu8.com/S/PRME\">Prime Medicine, Inc.</a> (Nasdaq: PRME), a biotechnology company focused on developing innovative genetic therapies, has announced a significant boost in funding with up to $24 million from the Cystic Fibrosis Foundation (CF Foundation). This additional investment aims to accelerate the development of Prime Editors, which are designed to permanently correct cystic fibrosis-related lung disease. The funding will be provided in two tranches, contingent on certain closing conditions and scientific milestones. Prime Medicine plans to initially target the G542X mutation, a prevalent CF-causing nonsense mutation with no current therapies available. The CF Foundation's commitment underscores its confidence in Prime Editing as a transformative approach for cystic fibrosis, with the potential to treat a majority of those affected by the disease. This funding is a continuation of the support established in a January 2024 agreement and highlights the strategic collaboration between Prime Medicine and the CF Foundation to drive innovative solutions for cystic fibrosis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9495225-en) on July 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prime Medicine Secures Up to $24 Million from CF Foundation to Advance Prime Editing Treatments for Cystic Fibrosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrime Medicine Secures Up to $24 Million from CF Foundation to Advance Prime Editing Treatments for Cystic Fibrosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-16 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Prime Medicine Secures Up to $24 Million from CF Foundation to Advance Prime Editing Treatments for Cystic Fibrosis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CAMBRIDGE, Mass., July 16, 2025 - <a href=\"https://laohu8.com/S/PRME\">Prime Medicine, Inc.</a> (Nasdaq: PRME), a biotechnology company focused on developing innovative genetic therapies, has announced a significant boost in funding with up to $24 million from the Cystic Fibrosis Foundation (CF Foundation). This additional investment aims to accelerate the development of Prime Editors, which are designed to permanently correct cystic fibrosis-related lung disease. The funding will be provided in two tranches, contingent on certain closing conditions and scientific milestones. Prime Medicine plans to initially target the G542X mutation, a prevalent CF-causing nonsense mutation with no current therapies available. The CF Foundation's commitment underscores its confidence in Prime Editing as a transformative approach for cystic fibrosis, with the potential to treat a majority of those affected by the disease. This funding is a continuation of the support established in a January 2024 agreement and highlights the strategic collaboration between Prime Medicine and the CF Foundation to drive innovative solutions for cystic fibrosis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9495225-en) on July 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDL76zrG4:1","article_id":"2551205147","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551205147","pubTimestamp":1752663625,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CAMBRIDGE, Mass., July 16, 2025 - Prime Medicine, Inc. , a biotechnology company focused on developing innovative genetic therapies, has announced a significant boost in funding with up to $24 million from the Cystic Fibrosis Foundation . This additional investment aims to accelerate the development of Prime Editors, which are designed to permanently correct cystic fibrosis-related lung disease. The funding will be provided in two tranches, contingent on certain closing conditions and scientific milestones. Prime Medicine plans to initially target the G542X mutation, a prevalent CF-causing nonsense mutation with no current therapies available. The CF Foundation's commitment underscores its confidence in Prime Editing as a transformative approach for cystic fibrosis, with the potential to treat a majority of those affected by the disease. This funding is a continuation of the support established in a January 2024 agreement and highlights the strategic collaboration between Prime Medicin","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","PRME":"Prime Medicine, Inc.","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"Prime Medicine从CF基金会获得高达2400万美元的资金，用于推进囊性纤维化的Prime编辑治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRME":0.9,"NDAQ":0.9},"content_text":"Prime Medicine Secures Up to $24 Million from CF Foundation to Advance Prime Editing Treatments for Cystic Fibrosis\n    \n\n        CAMBRIDGE, Mass., July 16, 2025 - Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company focused on developing innovative genetic therapies, has announced a significant boost in funding with up to $24 million from the Cystic Fibrosis Foundation (CF Foundation). This additional investment aims to accelerate the development of Prime Editors, which are designed to permanently correct cystic fibrosis-related lung disease. The funding will be provided in two tranches, contingent on certain closing conditions and scientific milestones. Prime Medicine plans to initially target the G542X mutation, a prevalent CF-causing nonsense mutation with no current therapies available. The CF Foundation's commitment underscores its confidence in Prime Editing as a transformative approach for cystic fibrosis, with the potential to treat a majority of those affected by the disease. This funding is a continuation of the support established in a January 2024 agreement and highlights the strategic collaboration between Prime Medicine and the CF Foundation to drive innovative solutions for cystic fibrosis.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9495225-en) on July 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}